Daiichi Sankyo Company, Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSNKY research report →
About the company
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise that encompasses the entire lifecycle of drug development, from pioneering research and development to manufacturing, importation, marketing, and worldwide distribution of its medicinal products. Its extensive and diverse portfolio features numerous key pharmaceutical offerings: Oncology: This includes trastuzumab deruxtecan (an anti-HER2 antibody-drug conjugate for cancer treatment), gefitinib for malignant tumors, bicalutamide for prostate cancer, and tamoxifen, an anti-breast cancer agent. Cardiovascular and Metabolic Health: The company provides teneligliptin and a combination of teneligliptin/canagliflozin for managing type 2 diabetes mellitus, along with colesevelam for both hypercholesterolemia and type 2 diabetes.
- CEO
- Hiroyuki Okuzawa
- IPO
- 2008
- Employees
- 18,726
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $29.93B
- P/E
- 18.87
- P/S
- 2.27
- P/B
- 2.92
- EV/EBITDA
- 13.82
- Div Yield
- 2.94%
- Gross Margin
- 68.49%
- Op Margin
- 9.80%
- Net Margin
- 12.24%
- ROE
- 15.74%
- ROIC
- 6.58%
- Revenue
- $2.25T · 19.34%
- Net Income
- $275.55B · -6.83%
- EPS
- $148.60 · -4.72%
- Op Income
- $219.81B
- FCF YoY
- 59.88%
- 52W High
- $27.50
- 52W Low
- $14.98
- 50D MA
- $16.30
- 200D MA
- $20.12
- Beta
- -0.15
- Avg Volume
- 315.42K
Get TickerSpark's AI analysis on DSNKY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DSNKY coverage
Recent articles, reports, and earnings notes.
No research on DSNKY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DSNKY report →Similar companies
Peers in the same neighborhood.